Literature DB >> 18274722

[Diagnosis of urothelial carcinoma].

A Karl1, D Zaak, D Tilki, E Hungerhuber, M Staehler, S Denzinger, P Stanislaus, S Tritschler, F Strittmatter, C Stief, M Burger.   

Abstract

Bladder cancer represents the fifth most common malignancy in the US. In Germany we face 25,000 new incidences of urothelial cancers every year. At present a variety of different techniques is available for the diagnosis of bladder cancer. On the one hand techniques are needed that show the possible presence of a tumour and on the other hand procedures that can confirm a lesion to be a tumour, like in most cases histology does. The following article gives an overview of the currently used standards in the diagnosis of urothelial cancer. Also new techniques for diagnosis and surveillance of urothelial cancer are discussed. The combination of white light endoscopy and urine cytology is currently considered the gold standard for diagnosis. Transurethral biopsies or TUR-BT subsequently follow in the case of positive findings. To optimize the sensitivity and lower the recurrence rate as well as the residual tumour rate, fluorescence endoscopy can be used as an additional approach. Also urine-based markers play an important role in the diagnosis and surveillance of urothelial carcinomas, but cannot yet be recommended as a single procedure in the routine diagnosis of bladder tumour.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18274722     DOI: 10.1007/s00120-008-1675-8

Source DB:  PubMed          Journal:  Urologe A        ISSN: 0340-2592            Impact factor:   0.639


  20 in total

1.  A comparison of BTA stat, hemoglobin dipstick, telomerase and Vysis UroVysion assays for the detection of urothelial carcinoma in urine.

Authors:  Kevin C Halling; Walter King; Irina A Sokolova; R Jeffrey Karnes; Reid G Meyer; Eric L Powell; Thomas J Sebo; John C Cheville; Amy C Clayton; Kelly L Krajnik; Thomas A Ebert; Robert E Nelson; Haleh M Burkhardt; Sanjay Ramakumar; Christopher S Stewart; Vernon S Pankratz; Michael M Lieber; Michael L Blute; Horst Zincke; Steven A Seelig; Robert B Jenkins; Dennis J O'Kane
Journal:  J Urol       Date:  2002-05       Impact factor: 7.450

2.  Improved detection of recurrent bladder cancer using the Bard BTA stat Test.

Authors:  M F Sarosdy; M A Hudson; W J Ellis; M S Soloway; R deVere White; J Sheinfeld; M V Jarowenko; P F Schellhammer; E W Schervish; J V Patel; G W Chodak; D L Lamm; R D Johnson; M Henderson; G Adams; B A Blumenstein; K R Thoelke; R D Pfalzgraf; H A Murchison; S L Brunelle
Journal:  Urology       Date:  1997-09       Impact factor: 2.649

3.  Seven years' experience with 5-aminolevulinic acid in detection of transitional cell carcinoma of the bladder.

Authors:  Edwin Hungerhuber; Herbert Stepp; Martin Kriegmair; Christian Stief; Alfons Hofstetter; Arndt Hartmann; Ruth Knuechel; Alexander Karl; Stefan Tritschler; Dirk Zaak
Journal:  Urology       Date:  2007-02       Impact factor: 2.649

4.  A comparison of urinary nuclear matrix protein-22 and bladder tumour antigen tests with voided urinary cytology in detecting and following bladder cancer: the prognostic value of false-positive results.

Authors:  V Poulakis; U Witzsch; R De Vries; H M Altmannsberger; M J Manyak; E Becht
Journal:  BJU Int       Date:  2001-11       Impact factor: 5.588

Review 5.  The value of a second transurethral resection in evaluating patients with bladder tumours.

Authors:  Makram Miladi; Michaël Peyromaure; Marc Zerbib; Djillali Saïghi; Bernard Debré
Journal:  Eur Urol       Date:  2003-03       Impact factor: 20.096

Review 6.  Non-invasive urothelial neoplasms: according to the most recent WHO classification.

Authors:  Antonio Lopez-Beltran; Rodolfo Montironi
Journal:  Eur Urol       Date:  2004-08       Impact factor: 20.096

7.  A comparison of hexaminolevulinate fluorescence cystoscopy and white light cystoscopy for the detection of carcinoma in situ in patients with bladder cancer: a phase III, multicenter study.

Authors:  Yves Fradet; H Barton Grossman; Leonard Gomella; Seth Lerner; Michael Cookson; David Albala; Michael J Droller
Journal:  J Urol       Date:  2007-05-11       Impact factor: 7.450

8.  Bladder tumor staging: comparison of contrast-enhanced CT, T1- and T2-weighted MR imaging, dynamic gadolinium-enhanced imaging, and late gadolinium-enhanced imaging.

Authors:  B Kim; R C Semelka; S M Ascher; D B Chalpin; P R Carroll; H Hricak
Journal:  Radiology       Date:  1994-10       Impact factor: 11.105

9.  Newly diagnosed bladder cancer: the relationship of initial symptoms, degree of microhematuria and tumor marker status.

Authors:  Hans Boman; Hans Hedelin; Stefan Jacobsson; Sten Holmäng
Journal:  J Urol       Date:  2002-11       Impact factor: 7.450

10.  Role of 5-aminolevulinic acid in the detection of urothelial premalignant lesions.

Authors:  Dirk Zaak; Edwin Hungerhuber; Peter Schneede; Herbert Stepp; Dominic Frimberger; Stefan Corvin; Nikolaus Schmeller; Martin Kriegmair; Alfons Hofstetter; Ruth Knuechel; Ruth Knöchel
Journal:  Cancer       Date:  2002-09-15       Impact factor: 6.860

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.